Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PPP5C | P53041 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4867998 | 0.95 | CYP1A2 (0.51) | CYP1A2CA1CA9PRKCAKMT2A | |
| SCHEMBL1989091 | 0.93 | CYP1A2 (0.54) | CYP1A2CA1CA9PRKCA | |
| SCHEMBL1986800 | 0.93 | CYP1A2 (0.54) | CYP1A2CA1CA9PRKCA | |
| SCHEMBL1983831 | 0.93 | CYP1A2 (0.54) | CYP1A2CA1CA9PRKCA | |
| SCHEMBL8393422 | 0.93 | CYP1A2 (0.54) | CYP1A2CA1CA9PRKCA | |
| SCHEMBL1985465 | 0.93 | CYP1A2 (0.54) | CYP1A2CA1CA9PRKCA | |
| SCHEMBL7595469 | 0.85 | CYP1A2 (0.45) | CYP1A2PRKCAKMT2APOLB | |
| SCHEMBL7590787 | 0.83 | CYP1A2 (0.44) | CYP1A2PRKCAKMT2A | |
| SCHEMBL2317576 | 0.81 | — | — | |
| SCHEMBL16281629 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716131-B1 | NOVEL ALKOXYLACTONES, ALKOXYLACTAMES AND ALKOXYTHIOLACTAMES FOR CONTROLLING PROCESSES BASED ON MICROBIAL INTERACTION | HENKEL AG & CO KGAA (DE) | 2011-06-29 | — | — | EP | disclosed |
| US-7825268-B2 | Alkoxylactones, alkoxylactams and alkoxythiolactams for controlling processes based on microbial interaction | HENKEL AG & CO. KGAA (DE) | 2010-11-02 | — | — | US | disclosed |
| US-20080207734-A1 | Novel alkoxylactones, alkoxylactams and alkoxythiolactams for controlling processes based on microbial interaction | HENKEL AG & CO. KGAA (DE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207734-A1 | Novel alkoxylactones, alkoxylactams and alkoxythiolactams for controlling processes based on microbial interaction | COASY, C1S, HACL2 | CYP1A2 363/4885CA1 4428/4885CA9 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.